Now, in an environment clouded by the Korean stem-cell scandal, how will a company that just saw its stock share value decrease
by 66% manage to convince venture capitalists to fork over more money?
It won't be easy. While it's true that the federal government is usually the prime financial contributor to emerging medical
technologies, the stem-cell environment still has an uphill battle.
With the scandal in Korea and a lack of quantifiable research available, venture capitalists are understandably skittish.
I doubt that's going to change anytime soon.
Celebrity author and business/finance commentator for CNN and Fox News, Brian O'Connell has written for The Wall Street Journal and Newsweek, 79 Radcliffe Drive,Doylestown, PA 18901, 267.880.3144, fax 267.880.1939